reSee.it - Related Video Feed

In the presented remarks, the speaker engages the audience with a series of questions intended to reveal potential overlaps among health sector entities. The questions ask the audience to raise their hands if their companies own or control a health insurance division; if they also employ health care providers or own clinics, specialty pharmacies, or any other medical practice or pharmacy; if they own or control a pharmacy benefit manager (PBM); and if they lead a publicly traded company at which they have a legal responsibility to maximize shareholder value. These questions are designed to surface the breadth of influence held by large health care firms. The speaker asserts that the audience’s responses demonstrate a broader pattern: the largest health insurance companies are not limited to providing insurance alone. Instead, they are also involved in delivering medical services and operating pharmacies. The speaker notes that these entities diagnose and decide treatment for patients, indicating an active role in clinical decision-making beyond underwriting risk or processing claims. Further, the speaker highlights that these same large insurers are also PBMs, describing PBMs as “another form of middlemen managing drug benefits.” This point emphasizes a layered structure in which a single company can influence which drugs are preferred, covered, or reimbursed, thereby affecting patient access and pricing across the drug supply chain. The speaker concludes that these combined roles signify that large health insurers are “increasingly controlling every aspect of our health care system.” This characterization suggests a consolidation of functions—from coverage and care provision to drug benefit management—under a few dominant corporate entities. In summary, the speaker’s lines of inquiry and subsequent claims illustrate a perceived convergence: health insurance companies are simultaneously insurers, medical providers, pharmacies, and PBMs, and they are expanding their control over multiple facets of health care delivery and economics. The overarching assertion is that the largest players in the health care landscape occupy a multifaceted, integrated position that spans diagnosis, treatment decisions, pharmacy operations, and drug benefit management, contributing to a broader phenomenon of comprehensive control within the system.

I found something interesting for Elon and the Doge team regarding Medicare. In 2022, Medicare filled 85,000 prescriptions for Perfinidone at $8,000 each, totaling $680 million. At my cost-plus pharmacy, the same prescription is only $200. Filling all 85,000 prescriptions with me would only cost $17 million. Medicare is overpaying by $663 million annually because Pharmacy Benefits Managers (PBMs) get a percentage of the cost, incentivizing them to inflate prices. The easy solution is to cancel the PBM contracts and use actual costs. If you want to check if PBMs have been raising the cost of your medications, go to forestparkpharmacy.com and check our price to see how much you could save.

I am Melissa McAtee, the Pfizer whistleblower. I want to clarify that I am not suicidal and have a happy life with my family. If anything happens to me, it is because of big pharma, big tech, or big gov. My family and I are not involved. Thank you. Translation: I am Melissa McAtee, the Pfizer whistleblower. I want to clarify that I am not suicidal and have a happy life with my family. If anything happens to me, it is because of big pharma, big tech, or big gov. My family and I are not involved. Thank you.

My name is Gwen Olsen, a former pharmaceutical industry veteran. The industry focuses on maintaining diseases, not curing them. Psychiatric drugs keep patients reliant on medications for life. Many drugs are no more effective than placebos, with exercise often proving more beneficial. The pharmaceutical industry prioritizes profit over patient well-being, pushing unnecessary medications. It's crucial to educate yourself on alternative health options to avoid becoming a lifelong pharmaceutical customer. Take charge of your health, share knowledge, and prevent loved ones from falling victim to unnecessary medications. Thank you. Translation: The speaker, Gwen Olsen, discusses the pharmaceutical industry's focus on maintaining diseases rather than curing them, highlighting the ineffectiveness of many drugs and the importance of educating oneself on alternative health options.

You've been served, Pfizer Corporation. This is considered official service. We’re not leaving until this is done. You've been served for crimes against humanity. We’ve completed the service. You have no obligation to respond, but the notice has been delivered. Let's go.

Speaker quotes Medicare guidelines: "A treatment plan that seeks to prevent disease and enhance the quality of life, or therapy that is performed to maintain or prevent deterioration of a chronic disease is deemed not medically necessary." He notes that Medicare decisions influence others, saying: "People who are in the insurance business know what Medicare decides sooner or later will be what other insurance companies decide to do." He adds: "Medicare sort of sets the table and everybody else sort of just follows along comes to dinner." He emphasizes that "Bottom line is, just because it's not covered doesn't mean it's not good. It just means that they consider it not medically necessary." He closes with audience engagement and signs off: "Doctor. Dave Morrison, Magnolia Medical Center here in Murfreesboro, Tennessee."

It's frustrating trying to make this new vaccine work. I understand the emotions involved; it's tough. Don't cry, everything will be okay.

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Drug companies are teaming up with big agencies and tech platforms to censor social communication, limiting our ability to share information. Manufacturers and the FDA manipulate science to meet regulatory requirements, leading to harmful products. The regulatory system is a facade, and the public is paying for products that harm instead of help. This manipulation must be stopped. Translation: Drug companies are working with big agencies and tech platforms to censor communication, preventing us from sharing information. Manufacturers and the FDA manipulate science to meet regulations, resulting in harmful products. The regulatory system is a facade, and the public is paying for products that harm instead of help. This manipulation must be stopped.

I am currently not allowed to take the vaccine due to legal restrictions. There is a priority list for vaccination, and we are not permitted to participate in clinical trials as company employees. Our focus is on ensuring the functionality of our teams and the company as a whole. We are working towards finding a legal and fair solution to this situation, prioritizing the vaccination of our coworkers and partners.

Big pharma will likely profit significantly from this medication, which is intended for long-term or potentially lifelong use.

I'm Tiffany Doper, the manager of the COVID unit in CCU. My team will be among the first to receive the vaccine. Sorry, I'm feeling dizzy.

Medicare overspent on dimethyl fumarate in 2022, paying $590 million for a drug I offer at $65 per prescription. This discrepancy highlights how Pharmacy Benefits Managers (PBMs) inflate drug costs to increase their profits. Medicare's PBM charged them $3,800 per prescription when the real price is only $65. This PBM price gouging cost Medicare $580 million on just this one drug. The solution is simple: eliminate PBM contracts to save money. Also, your insurance likely uses a PBM, overcharging you too. Check if you're overpaying for your medications at fourthparkpharmacy.com to use our price checker.

Speaker 0: The pharmacy benefit managers. Speaker 1: Think of it like this. So you go to a restaurant and you order a burger. Okay? And let's say that burger costs $15. But before your order goes through, some guy steps in and says, hold on. If the restaurant wants to sell you that burger, they need to pay me $5. And if not, you can't have the burger. Speaker 0: Think of them as the toll bridge between you and drug prices. Speaker 1: But the PBM isn't just collecting the toll. They're also controlling which cars can pass. They own the bridge. They set the price of gas. They use their contracts to profit off of everyone crossing. Speaker 1: So the PBM charges the employer a very high price. It pays the pharmacy a very low price, and it keeps the difference, and that's called spread pricing.

You want to speak with her? I can get her on the call. We're dealing with numerous denials weekly. My name is Julie, and we face significant challenges with insurance companies. Despite our efforts, we receive cease and desist letters for speaking out on social media. Patients share their struggles with chronic pain and the impact of insurance decisions on their treatment. We work tirelessly to secure necessary medications, often spending countless hours on appeals. Even experienced healthcare administrators find the process exhausting. Recently, an insurance company reversed a denial after our appeal, highlighting the importance of persistence. Patients question how insurers determine their treatment needs, especially when it affects their quality of life. The current health insurance system in the U.S. is deeply flawed and needs reform.

Speaker 0 expresses frustration over a price discrepancy in a prescription transaction. The core facts cited are: a medication that costs $4 to dispense, when billed to the insurance, results in the patient being charged $97.06. Speaker 0 repeats the puzzling situation: “We have a claim for a prescription that costs less than $4. The insurance wants to charge the patient $97.” The concern is the patient’s likely reaction: they will be yelled at and blame CVS for the high price set by their insurance, even though the dispensing cost is described as less than $4. Speaker 0 highlights the misalignment between the pharmacy’s dispensing cost and the amount the patient is asked to pay after insurance processing, indicating a breakdown in the expected pricing flow from the pharmacy to insurance to patient. The dialogue underscores the emotional and reputational pressure on the pharmacy staff when patients perceive the price as excessive, regardless of where the markup originates. The closing sentiment, “Love you CVS,” signals a mixture of familiarity and exasperation with the CVS system or process involved in this pricing scenario, though the exact sentiment toward CVS is not elaborated beyond that line.

I am Melissa McAtee, the Pfizer whistleblower. I want to make it clear that I am not suicidal. My family is happy and healthy, with no issues. If anything happens to me, it is because of big pharma, big tech, or big gov. My family and I are not involved. Thank you. Translation: I am Melissa McAtee, the Pfizer whistleblower. I want to clarify that I am not suicidal. My family is happy and healthy, with no issues. If anything happens to me, it is because of big pharma, big tech, or big gov. My family and I are not involved. Thank you.

I am Tiffany Doper, the manager of the COVID unit in CCU. My team will be among the first to receive the vaccine. Apologies, I am feeling dizzy.

I received a letter from my health insurance stating they won't cover one of my chemotherapy sessions costing $15,000. My doctor had previously confirmed approval for my treatment, so I'm confused and worried this could mean they won't cover future sessions. I rely on chemotherapy every three weeks for my stage 4 cancer, and I can't afford that cost. If they stop covering it, my doctor might have to switch me to a cheaper treatment that may not work as effectively. My recent MRI showed my tumors have shrunk slightly, but the risk of nerve damage and paralysis was real. This letter feels like a threat to my life, as it jeopardizes my access to life-saving treatment.

Speaker 0 is frustrated because another store refused to fill their prescription, while Speaker 1 explains that they don't have the medication in stock. Speaker 0 mentions Ivermectin, but Speaker 1 clarifies that they don't have it and even if they did, they couldn't fill it due to quantity restrictions and lack of FDA approval. Speaker 0 argues that Wellbutrin is also not FDA approved for smoking cessation, but Speaker 1 doesn't provide a satisfactory answer. The conversation ends with Speaker 0 expressing dissatisfaction with Speaker 1's response.

Speaker 0 asks if the person has insurance, but Speaker 1 says there's nothing they can do and they don't have insurance. Speaker 0 repeats the question multiple times, but Speaker 1 insists that there is nothing they can do. The conversation ends with Speaker 1 telling Speaker 0 not to do something.

You want to talk to her? I can get her on the call. We're dealing with a lot of denials—about 50 a week. My name is Julie, the practice manager. We’ve faced backlash from insurance companies like Aetna and Cigna for speaking out on social media. Patients describe their struggles with chronic pain and the impact on their lives. After starting treatment, one patient felt relief, only to face insurance denials for necessary infusions. We work hard to appeal these decisions, spending countless hours on cases. Even experienced administrators find the process exhausting. However, we’ve had success in getting approvals after appeals. Patients deserve better; insurance companies shouldn’t dictate their quality of life. The health insurance system in the U.S. is fundamentally flawed and needs change.

I just had a frustrating call with an insurance company regarding a patient's care. The insurance doctor questioned why I ordered certain treatments for a baby, despite established guidelines. I had the guidelines in front of me, but she didn't even have her password to access them. After explaining the medical necessity, she reluctantly agreed to approve the request but suggested that maybe the baby didn’t need such intensive care. I firmly stated that we take infant health very seriously. It’s disheartening to see some doctors prioritize insurance profits over patient care. There should be a clear line drawn when it comes to the value of human life in medicine.

I'm on day five of helping to cut waste, and today I found that Medicare is overpaying for Aripiprazole. In 2022, this medication was dispensed 7.2 million times at an average of $208 each. Medicare spent $1.5 billion in one year on this one drug. At my pharmacy, without insurance, the same medication costs $12. Filling all 7.2 million prescriptions at my price would cost $86 million. That means over $1.4 billion was wasted due to Medicare's use of pharmacy benefits managers (PBMs). PBMs use an inflated price called AWP, pretend to discount it, and then send you to their pharmacies to collect the profits. This system is easily fixed by canceling PBM contracts, ditching the made-up prices, and returning to reality. To see how much you've been overcharged, visit forestparkpharmacy.com and use our price checker.

I am Melissa McAtee, the Pfizer whistleblower, clarifying that I am not suicidal. My family is happy and healthy, with no issues. If anything happens to me, it is because of big pharma, big tech, or big gov. Nothing is self-inflicted or related to my family or friends. Thank you. Translation: I am Melissa McAtee, the Pfizer whistleblower, confirming that I am not suicidal. My family is happy and healthy, with no problems. If anything happens to me, it is because of big pharmaceutical companies, big technology companies, or the government. It is not related to me, my family, or my friends. Thank you.